pemvidutide vs Zabopegdutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline

pemvidutide

Developed by Altimmune

Phase 3 in MASH / NASHpeptide
Partial signal

NCT05989711 · Phase 2 · completed

IMPACT was a randomized, quadruple-blind, placebo-controlled Phase 2b in 212 patients with MASH with two biopsy co-primary endpoints. MASH resolution was met at both doses; fibrosis improvement did not reach statistical significance, so the primary comparison was only partly met and the grade is moderate.

Next expected readout: December 2028 · NCT07795164 (registry estimate)

Reported efficacy

Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis (24 weeks); Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) (24 weeks); Incidence of Treatment Emergent Adverse Events (52 weeks): Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). (mixed)

Result source: NCT05989711

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in MASH / NASHpeptide
Partial signal

NCT06410924 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.

Reported efficacy

Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF (12 weeks): Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. (met)

Result source: NCT06410924

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointpemvidutideZabopegdutide
MASH resolution without fibrosis worsening52.1% vs 19.1%a+33 vs placebopemvidutide 1.8mg · wk 24NCT05989711
1 other result
  • 59.1% vs 19.1% pemvidutide 1.2mg · wk 24 · Phase 2 · primary NCT05989711
—Not reported
Fibrosis stage, change—Trial running · NCT07795164—Not reported
Liver fat (MRI-PDFF), change—Trial running · NCT07795164—Not reported
ALT, change—Trial running · NCT07795164—Not reported

MASH resolution without fibrosis worsening

pemvidutide
52.1% vs 19.1%a+33 vs placebopemvidutide 1.8mg · wk 24NCT05989711
1 other result
  • 59.1% vs 19.1% pemvidutide 1.2mg · wk 24 · Phase 2 · primary NCT05989711
Zabopegdutide
—Not reported

Fibrosis stage, change

pemvidutide
—Trial running · NCT07795164
Zabopegdutide
—Not reported

Liver fat (MRI-PDFF), change

pemvidutide
—Trial running · NCT07795164
Zabopegdutide
—Not reported

ALT, change

pemvidutide
—Trial running · NCT07795164
Zabopegdutide
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

pemvidutide

NASH Resolution Without Fibrosis Worsening 52.1% vs 19.1% placebo @ 24wkpemvidutide 1.8mg
responder rate · % of participants
NCT05989711 · Phase 2 · sponsor-reported, not registry data
show 1 more result
59.1% vs 19.1% placebo @ 24wkpemvidutide 1.2mg
NCT05989711 · Phase 2 · sponsor-reported, not registry data

Zabopegdutide

MRI-PDFF ≥30% 75.8% vs 11.8% placebo @ 12wk
responder rate · % of participants
NCT06410924 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pemvidutide's landscape · Zabopegdutide's landscape